Mycoplanecin

Class: DNA synthesis inhibitor (DnaN inhibitor)

Details of activity:	Active against Mycobacterium tuberculosis, Mycobacterium phlei, Mycobacterium kansasii, Mycobacterium fortuitum, and Mycobacterium bovis
Description:	Natural product from Actinoplanes awajinensis subsp. Mycoplanecinus (rediscovered in genome mining for griselimycin-like biosynthetic gene clusters in actinobacteria); derivatives reported elsewhere; tolerated by mice (400-3,000 mg/kg) when administered subcutaneously or orally
Institute where first reported:	Fermentation Research Laboratories, Sankyo Co., Ltd.; Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), and Department of Pharmacy, Saarland University, 66123, Saarbrücken, Germany
Year first mentioned:	1983
Development status:	Experimental

Chemical structure(s):
Canonical SMILES:	CCC1CC(C(=O)N(C)C2C(C)OC(=O)CNC(=O)C(CC(C)C)N(C)C(=O)C3CCCN3C(=O)C(C(C)C)N(C)C(=O)C(CCC(C)C)NC(=O)C4CC(C)CN4C(=O)C(CC(C)C)NC2=O)N(C1)C(=O)C(C(C)C)N(C)C(=O)C(=O)CC
Isomeric SMILES:	CCC1CC(N(C1)C(=O)C(C(C)C)N(C)C(=O)C(=O)CC)C(=O)N(C)C2C(OC(=O)CNC(=O)C(N(C(=O)C3CCCN3C(=O)C(N(C(=O)C(NC(=O)C4CC(CN4C(=O)C(NC2=O)CC(C)C)C)CCC(C)C)C)C(C)C)C)CC(C)C)C
InChI:	InChI=1S/C61H102N10O13/c1-19-40-29-46(71(32-40)61(83)50(37(11)12)67(17)59(81)47(72)20-2)58(80)68(18)51-39(14)84-48(73)30-62-52(74)44(27-35(7)8)65(15)57(79)43-22-21-25-69(43)60(82)49(36(9)10)66(16)55(77)41(24-23-33(3)4)63-53(75)45-28-38(13)31-70(45)56(78)42(26-34(5)6)64-54(51)76/h33-46,49-51H,19-32H2,1-18H3,(H,62,74)(H,63,75)(H,64,76)
InChI Key:	ICFLLAYTOVAMGO-UHFFFAOYSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/197207

External links:
Main Source:	https://www.nature.com/articles/s41467-024-44953-5
Citations:	https://www.jstage.jst.go.jp/article/antibiotics1968/36/8/36_8_957/_article https://www.jstage.jst.go.jp/article/antibiotics1968/36/8/36_8_961/_pdf/-char/en